Related Experiment Video
Updated: Jan 29, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through
Fei Ma1, Xu Liu1, Shibo Zhou2
1Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Abstract:
LncRNAs have been proven to play crucial roles in various processes of breast cancer. LncRNA FGF13-AS1 has been identified as one of the 25 downregulated lncRNAs in breast cancer through analyzing data from two cohorts and TCGA by another group of our lab. In this study, we report that FGF13-AS1 expression is decreased in breast cancer tissue compared with corresponding normal tissue, and the downregulation of FGF13-AS1 is associated with poor prognosis. Functional studies show that FGF13-AS1 inhibits breast cancer cells proliferation, migration, and invasion by impairing glycolysis and stemness properties. Mechanistically, FGF13-AS1 reduces the half-life of c-Myc (Myc) mRNA by binding RNA-binding proteins, insulin-like growth factor 2 mRNA binding proteins (IGF2BPs) and disrupting the interaction between IGF2BPs and Myc mRNA. Furthermore, Myc transcriptionally inhibits FGF13-AS1, forming a feedback loop in this signaling pathway. These results reveal for the first time that FGF13-AS1 functions as a tumor suppressor by inhibiting glycolysis and stemness properties of breast cancer cells, and the FGF13-AS1/IGF2BPs/Myc feedback loop could be a novel therapeutic target for breast cancer patients.
Insights
Long non-coding RNA FGF13-AS1 acts as a tumor suppressor in breast cancer by inhibiting cell proliferation, migration, and invasion. Its downregulation is linked to poor prognosis, suggesting a new therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Long non-coding RNAs (lncRNAs) are critical in breast cancer development.
- LncRNA FGF13-AS1 is downregulated in breast cancer and associated with poor prognosis.
Purpose of the Study:
- To investigate the role of FGF13-AS1 in breast cancer.
- To elucidate the underlying molecular mechanisms of FGF13-AS1 action.
Main Methods:
- Analysis of FGF13-AS1 expression in breast cancer tissues.
- Functional assays to assess the impact of FGF13-AS1 on cell proliferation, migration, and invasion.
- Mechanistic studies involving RNA-binding proteins (IGF2BPs) and c-Myc mRNA stability.
Main Results:
- FGF13-AS1 expression is decreased in breast cancer tissues.
- FGF13-AS1 suppresses breast cancer cell proliferation, migration, and invasion by impairing glycolysis and stemness.
- FGF13-AS1 reduces c-Myc mRNA half-life by interacting with IGF2BPs, and c-Myc transcriptionally inhibits FGF13-AS1, forming a feedback loop.
Conclusions:
- FGF13-AS1 acts as a tumor suppressor in breast cancer.
- The FGF13-AS1/IGF2BPs/Myc feedback loop represents a potential therapeutic target for breast cancer treatment.
Related Concept Videos
Feedback Inhibition
Feedback Loops
Cell Signaling Feedback Loops
Negative feedback loops
Most signaling systems have negative feedback loops that can perform different functions such as output limiter, and adaptation.
Output limiter
Upon receiving an input signal, the cellular response rapidly increases until a threshold is reached. Beyond this threshold, a negative feedback loop...
lncRNA - Long Non-coding RNAs
Positive and Negative Feedback Loops
What is Glycolysis?
Cells make energy by breaking down macromolecules. Cellular respiration is the biochemical process that converts "food energy" (from the chemical bonds of macromolecules) into chemical energy in the form of adenosine triphosphate (ATP). The first step of this tightly regulated and intricate process is glycolysis. The word glycolysis originates from the Latin glyco (sugar) and lysis (breakdown). Glycolysis serves two main intracellular functions: generating ATP and generating...

